Net Good IndexSubmit a correction

Benefit Ledger · provisional · Biology

Profiling proteome-level amino acid substitutions in Alzheimer's disease brain tissue

As the most prevalent neurodegenerative disorder worldwide, Alzheimer's disease (AD) remains incompletely understood at the proteome level. In particular, current studies on amino acid (AA) substitutions have predominantly relied on genomic and transcriptomic profiling. Proteome-scale AA substitutions remain largely uncharacterized. Nevertheless, alterations at the DNA and RNA levels cannot fully recapitulate the spectrum of AA substitutions observed at the proteome level. This critical research gap persists largely due to the inherent analytical challenges posed by large-scale proteomic datas

Tier 1 UsefulMethodology 0.2
Submit a correction

Current score

+0.00

1 base · Useful (tier 1 of 5, 1 pts)
× 0.1000 attribution · Minor documented assistance
× 0.2000 evidence · Developer announcement
× 0.2000 realization · Proposed
× 0.5000 durability · Medium-term
Event-level product before credit split: 0.00

Ingest update: independent source raised evidence; added a follow-up source. Score remains provisional until review.

What happened

As the most prevalent neurodegenerative disorder worldwide, Alzheimer's disease (AD) remains incompletely understood at the proteome level. In particular, current studies on amino acid (AA) substitutions have predominantly relied on genomic and transcriptomic profiling. Proteome-scale AA substitutions remain largely uncharacterized. Nevertheless, alterations at the DNA and RNA levels cannot fully recapitulate the spectrum of AA substitutions observed at the proteome level. This critical research gap persists largely due to the inherent analytical challenges posed by large-scale proteomic datasets. In this study, we address this limitation by analyzing two independent AD proteomic datasets, AMP-AD and PXD013753, using PIPI-C, an open-search mass spectrometry engine capable of resolving multiple co-occurring modifications per peptide. We introduce a pipeline that enables the characterization of AA substitutions at the proteome level and the dissection of regulatory functions of key proteins with such substitutions. In both datasets, we observe that, after controlling for ambiguous post-translational modification mass shifts, the N>M substitution is the most frequent variant among N>X substitutions in the AD data. Furthermore, among the 701 overlapping proteins shared by the two datasets, we identified 6 literature-reported substitution sites, including residues 242 and 352 in glial fibrillary acidic protein, site 370 in actin gamma 1, as well as sites 111, 115, and 116 in hemoglobin subunit beta. Since most reported AA substitutions rely on genomic or transcriptomic evidence, and our pipeline adopts rigorous false-positive controls, those unreported substitutions are presumably detectable only via proteomic methods, emphasizing the unique value of our proteome-based substitutomics workflow for AD research. Update (2026-09-16): OpenAI to regularly disclose AI misbehavior, warns safety challenges remain - reuters.com. OpenAI to regularly disclose AI misbehavior, warns safety challenges remain  reuters.com

Model attribution

Unspecified AI system
Version unspecified
+0.00

Unspecified

Unspecified system mentioned or implied by a news item. Remap to a named release when identified.

News ingest does not infer a named model from the publisher alone. Attribution stays unspecified until a release is identified.

Attribution 0.1000 · Credit share 100% · Unknown

Claims

  • Profiling proteome-level amino acid substitutions in Alzheimer's disease brain tissue

    outcome · supported

Sources

primary sources

independent sources

Revision history

  • 15 Sep 2026 · 0.00 → 0.00

    Auto-published from news ingest.

  • 17 Sep 2026 · 0.00 → 0.00

    Ingest update: independent source raised evidence; added a follow-up source.